Table 1.
Current clinical trials involving radiation and HDAC inhibitors
| HDAC inhibitor | Chemotherapeutic or biological agent(s) | Type of malignancy | Phase | Trial identifier |
|---|---|---|---|---|
| Panobinostat | None | Prostate, oesophageal and head and neck cancer | I | NCT00670553 |
| Vorinostat | None | Brain metastases | I | NCT00838929 |
| Vorinostat | None | Brain metastases from non-small cell lung cancer | I | NCT00946673 |
| Vorinostat | None | Non-small cell lung cancer | I | NCT00821951 |
| Vorinostat | None | Pelvic cancer | I | NCT00455351 |
| Vorinostat* | None | Resistant/relapsed neuroblastoma | I | NCT01019850 |
| Vorinostat | Capecitabine | Non-metastatic pancreatic cancer | I | NCT00983268 |
| Vorinostat | Cisplatin | Squamous cell carcinoma of the oropharynx | I | NCT01064921 |
| Vorinostat | None | Locally advanced pancreatic cancer | I/II | NCT00831493 |
| Vorinostat | Temozolomide | Glioblastoma multiforme | I/II | NCT00731731 |
| Vorinostat | Paclitaxel | Inoperable stage III non-small cell lung cancer | I/II | NCT00662311 |
| Vorinostat | 5-FU | Pancreatic cancer | I/II | NCT00948688 |
| Valproic acid | Hydralazine, Cisplatin | Cervical cancer | II | NCT00404326 |
| Valproic acid | Temozolomide | Glioblastoma multiforme | II | NCT00302159 |
| Valproic acid | Bevacizumab | Paediatric high-grade gliomas | II | NCT00879437 |
*
Radiation form is the radioactive drug, iobenguane I 131.